ArticleFrontiers in neuroscience2026
Long-term follow-up of insomnia patients: symptom trajectories and predictors of treatment outcomes in a mobile-based CBT-I program.
Article in Frontiers in neuroscience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To investigate the longitudinal trajectories and prognostic factors of insomnia-related symptoms over a four-year follow-up period, using pharmacotherapy combined with a mobile-based cognitive behavioral therapy (CBT-I) for insomnia intervention. Methods: The clinical data including 1,022 patients of insomnia within January 2017 to January 2024 were obtained from the Sleep Center of the First People's Hospital of Yunnan Province. Participants completed standardized assessments via the "Good Sleep 365" mobile app, including Pittsburgh Sleep Quality Index (PSQI), Patient Health Questionnaire-9 (PHQ-9), Generalized Anxiety Disorder-7 (GAD-7), PHQ-15, Epworth Sleepiness Scale (ESS), and Insomnia Severity Index (ISI) at baseline and multiple follow-up points. Symptom trends were analyzed descriptively, and linear mixed-effects models were used to examine trajectories and identify baseline predictors of treatment outcomes. Results: PSQI, GAD-7, PHQ-9, and PHQ-15 scores improved markedly during the first 12 months after treatment, but showed mild relapse thereafter, whereas ESS scores remained largely stable. Higher baseline PHQ-9 scores predicted poorer outcomes across all symptom domains, while baseline GAD-7 showed limited independent prognostic value after adjusting for depression. Older age was associated with better treatment response ( Conclusion: Baseline depressive symptoms were the strongest predictor of long-term outcomes across sleep, mood, and somatic domains, whereas anxiety added only modest prognostic value. These findings highlight the importance of routine depression screening to guide risk stratification and follow-up in chronic insomnia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.